Qualifying a Novel Microbiome-targeting Compound as an Investigational New Drug (IND) Candidate to Improve Chemotherapy Outcomes
NCBiotech Grants & Loans
See the full listing of all NCBiotech grants and loans awarded since July 2012.
Organization
Symberix, Inc.
Award Date
Award Amount
250,000
Program Name
Small Business Research Loan
Program Category
Business Financing
Principal Investigator
Ward Peterson
Fiscal Year
2018
Region
Research Triangle
Project Description:
Symberix is a biopharmaceutical company focusing on developing a new class of therapeutics that target harmful activities of gut bacteria without killing beneficial bacteria. This project aims to qualify the company's proprietary symbiotic drug (SBXInh1) as an IND candidate to be developed to improve chemotherapy outcomes in cancer patients.